S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Urgent alert: open this for a huge profit potential (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Urgent alert: open this for a huge profit potential (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Urgent alert: open this for a huge profit potential (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Urgent alert: open this for a huge profit potential (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
TSE:EPI

ESSA Pharma (EPI) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free EPI Stock Alerts
Today's Range
N/A
50-Day Range
C$0.32
▼
C$0.32
52-Week Range
N/A
Volume
4,700 shs
Average Volume
68,239 shs
Market Capitalization
C$9.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About ESSA Pharma

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.

EPI Stock News Headlines

April 7, 2024 | uk.investing.com
ESSA Pharma Inc (EPIX)
January 30, 2024 | realmoney.thestreet.com
Essa Pharma initiated with bullish view at JonesResearch, here's why
April 19, 2024 | Altimetry (Ad)
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
January 26, 2024 | finance.yahoo.com
EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…
January 26, 2024 | msn.com
What's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?
January 25, 2024 | finanznachrichten.de
ESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
January 25, 2024 | finance.yahoo.com
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
December 12, 2023 | finance.yahoo.com
ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...
April 19, 2024 | Altimetry (Ad)
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
November 23, 2023 | finance.yahoo.com
Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Shares
November 7, 2023 | seekingalpha.com
ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance
October 24, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)
October 6, 2023 | benzinga.com
Prostate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
September 20, 2023 | seekingalpha.com
ESSA Pharma files for $200M mixed shelf offering - filing
August 9, 2023 | msn.com
Oppenheimer Reiterates Essa Pharma (EPIX) Outperform Recommendation
April 4, 2023 | msn.com
Why are EpiPens still so expensive?
February 13, 2023 | finance.yahoo.com
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
December 19, 2022 | finance.yahoo.com
EPIX: Advancing Multiple Clinical Trials in 2023…
November 16, 2022 | seekingalpha.com
ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer
October 31, 2022 | marketwatch.com
Essa Pharma Shares Drop 26% After Janssen Suspends Enrollment for Trials
October 31, 2022 | seekingalpha.com
ESSA drops 26% as Johnson & Johnson ends trial enrollment for lead asset
October 26, 2022 | finance.yahoo.com
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
October 26, 2022 | marketwatch.com
ESSA Pharma Surges 152% on Study Results for Lead Drug Candidate
October 26, 2022 | finance.yahoo.com
Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium
October 26, 2022 | seekingalpha.com
ESSA Pharma jumps 91% on Phase 1/2 data for prostate cancer therapy
August 10, 2022 | finance.yahoo.com
EPIX: Multiple Ongoing Studies of EPI-7386…
June 28, 2022 | finance.yahoo.com
ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer
See More Headlines
Receive EPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
TSE:EPI
CUSIP
N/A
CIK
N/A
Web
essapharmaceuticals.com
Phone
+1-778-3310962
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
29,102,000
Free Float
N/A
Market Cap
C$9.31 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Richard M. Glickman LL.D. (Age 57)
    Chairman of the Board
  • David Ross Parkinson M.D. (Age 67)
    President, Chief Executive Officer, Director
  • David Wood (Age 57)
    Chief Financial Officer
  • Peter Virsik
    Chief Operating Officer, Executive Vice President
  • Raymond L. Andersen (Age 67)
    Chief Technology Officer, Director
  • Marianne D. Sadar (Age 53)
    Chief Scientific Officer, Director
  • Frank Perabo (Age 50)
    Chief Medical Officer
  • Franklin M. Berger (Age 67)
    Director
  • Scott Requadt J.D.
    Director
  • Gary Sollis (Age 61)
    Director

Insiders


EPI Stock Analysis - Frequently Asked Questions

Is ESSA Pharma a good dividend stock?

ESSA Pharma (TSE:EPI) pays an annual dividend of C$0.22 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), bluebird bio (BLUE), Gray Television (GTN), Allergan (AGN), Cardiome Pharma (CRME), CEMEX (CX), Groupon (GRPN), Horizon Therapeutics Public (HZNP) and Tandem Diabetes Care (TNDM).

How do I buy shares of ESSA Pharma?

Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:EPI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes